After reading and considering the issues presented in the DMSB article, I have to conclude that things are not as bleak as I previously thought them to be; on the other hand, I do not feel things are quite as rosy as most on this board seem to believe. The trial extension was explained after the fact, not before, and to a skeptical eye such as mine, this causes some doubts; but, as per the article, there are at least some plausible potential reasons to account for the extended Phase III trial. Time will tell.
Will the market understand that effectiveness in meningococcemia means effectiveness in the other gram negative bacteria?
This is quite a leap of faith. If BPI exhibited overwhelming efficacy, leading to an early trial termination, then your statement would seem more reasonable. If the efficacy is marginal for meningococcemia, who is to say how this demonstrated efficacy will translate to other maladies, gram negative or not?
Just my non rosy opinions. |
